

Reference:	FOI.18917.25
Subject:	Oncology treatments
Date of Request:	24 November 2025

Requested:

1. Does your trust treat Polycythaemia Vera (ICD10 code D45)? If no, please provide the name of the trust that you refer Polycythaemia Vera patients to?
2. How many patients were initiated on Ruxolitinib (Jakavi) the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)
 - Myelofibrosis (ICD10 code D47.4)
 - Polycythaemia Vera (ICD10 code D45)
3. How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)
 - Momelotinib
 - Fedratinib
4. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?
 - Hydroxycarbamide
 - Interferon therapy

Response:

Where the figure in the table's below has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. Hywel Dda University Health Board (UHB) confirms it does treat Polycythaemia Vera.
2. The UHB provides within the table below, the number of patients diagnosed with Myelofibrosis or Polycythaemia Vera that were initiated on Ruxolitinib (Jakavi), during the period 1 June to 30 November 2025.

Condition	Number
Myelofibrosis	*
Polycythaemia Vera	0

3. The UHB confirms that no patients were initiated on Momelotinib or Fedratinib, for any condition, during the period 1 June to 30 November 2025.
4. The UHB provides within the table below, the number of patients diagnosed with Polycythaemia Vera that were treated with the listed treatments, during the period 1 June to 30 November 2025.

Treatment	Number
Hydroxycarbamide	*
Interferon therapy	0